Post by notamnkdmillionaire on Aug 11, 2015 11:56:52 GMT -5
Forgive me but I am a bit confused.
We heard a while back about Monash University and their inhaled oxytocin. Some believed it was Mannkind who was behind the tech but review of their info seemed to conclude they were using the tech that Pfizer used from their purchase of Nektar. Yes, the same failed tech found in Exubera.
Yesterday, Hakan (gotta be one of the most uninspiring CEOs I have ever heard) mentioned this:
At first I thought he was talking about Monash (since Mintaka starts with a "M" I was thinking he was talking about Monash and thought, "WHOA, I was wrong about my initial critique of those saying Mannkind was involved with 'that company' Monash."
Well, I wasn't wrong as this is a totally different foundation. But the question remains, why has Mannkind been so quiet about this?
One other note, I searched The Gates Foundation website and found no mention of Mintaka.
www.mintakafoundation.org/our-projects/maternal-health/
We heard a while back about Monash University and their inhaled oxytocin. Some believed it was Mannkind who was behind the tech but review of their info seemed to conclude they were using the tech that Pfizer used from their purchase of Nektar. Yes, the same failed tech found in Exubera.
Yesterday, Hakan (gotta be one of the most uninspiring CEOs I have ever heard) mentioned this:
Lastly, I want to call attention to MannKind being part of saving life at birth, a grand challenge for development program sponsored by the Gates Foundation. It was announced that the Mintaka Foundation for Medical Research was an award recipient for innovative solutions to prevent maternal infant deaths in hardest to reach regions of the world. The award recipients were selected from more than 750 submissions.
The Mintaka grant that powers MannKind’s effort for dosage form development was based on work performed at MannKind to develop a highly heat-resistant and noninvasive formula of oxytocin to reduce maternal death due to postpartum hemorrhage. We offer congratulations to the members of our clinical team who contributed to this research.
The Mintaka grant that powers MannKind’s effort for dosage form development was based on work performed at MannKind to develop a highly heat-resistant and noninvasive formula of oxytocin to reduce maternal death due to postpartum hemorrhage. We offer congratulations to the members of our clinical team who contributed to this research.
Well, I wasn't wrong as this is a totally different foundation. But the question remains, why has Mannkind been so quiet about this?
One other note, I searched The Gates Foundation website and found no mention of Mintaka.
www.mintakafoundation.org/our-projects/maternal-health/
/production/original_573352236.gif)
